Pliant Therapeutics, INC.: management transactions · United States · SEC (Form 4)

About Pliant Therapeutics, INC.

Pliant Therapeutics, Inc. (ticker: PLRX) is a United States–based biopharmaceutical company listed on the NASDAQ market. Headquartered in South San Francisco, California, and incorporated in Delaware in June 2015, the company is a clinical-stage developer built around a proprietary integrin biology platform. Its core strategy is to discover and develop therapeutics that modulate integrin-mediated pathways, with an initial emphasis on fibrosis biology and broader applications in oncology and other tissue-based diseases. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000080/plrxannualreport.pdf?utm_source=openai)) Pliant initially gained investor attention through bexotegrast, its lead candidate in idiopathic pulmonary fibrosis (IPF), a serious progressive lung disease with a high unmet medical need. In 2025, however, the company announced that it was discontinuing bexotegrast development in IPF following a safety review and an unfavorable risk-benefit assessment. That decision materially changed the company’s profile and led to a strategic restructuring, including lower operating costs and a leaner organization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1746473/000174647325000150/plrx-20250630.htm?utm_source=openai)) Scientifically, Pliant’s differentiation lies in its integrin-focused drug discovery engine. Management has described the platform as having broad applicability across multiple disease areas, and the company has also highlighted a tissue-targeted delivery approach that uses cell-specific integrin receptors to deliver payloads such as siRNAs to selected tissues. This makes Pliant more than a single-asset story; it is a platform company whose longer-term value depends on whether its discovery engine can produce multiple clinically meaningful programs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001746473/000174647326000037/plrx-20251231.htm?utm_source=openai)) From a competitive standpoint, PLRX remains a development-stage biotech with no commercial product revenues, so its investment case is driven by clinical data, regulatory progress, capital efficiency, and the company’s ability to pivot after setbacks. Following the discontinuation of the IPF program, Pliant has communicated plans to accelerate PLN-101095, with a Phase 1b indication expansion trial planned in 2026 for NSCLC and other tumor types with a mechanistic rationale for integrin inhibition. That pipeline evolution is important because it suggests the company is trying to reuse its scientific platform in new therapeutic settings rather than relying on a single pulmonary fibrosis asset. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm?utm_source=openai)) Geographically, the business is primarily US-centric, with corporate and operational activity in South San Francisco, California. For French-speaking investors, PLRX is therefore best understood as a US Nasdaq-listed specialty biotech with a high-risk/high-upside profile, where recent SEC filings and insider Form 4 activity are part of the normal disclosure stream that investors follow closely. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000080/plrxannualreport.pdf?utm_source=openai))